¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.
ÀÓ»ó µ¥ÀÌÅÍ ºÐ¼® ¼Ö·ç¼Ç ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é, ¼¼°è ÀÓ»ó µ¥ÀÌÅÍ ºÐ¼® ¼Ö·ç¼Ç ½ÃÀå ±Ô¸ð´Â 2024³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 6.8%ÀÇ °ý¸ñÇÒ ¸¸ÇÑ CAGR·Î È®´ëµÇ¾î 2030³â¿¡´Â 75¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ÀÇ·á±â°üÀÇ Ã·´Ü ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, Áý´Ü °Ç° °ü¸®¿¡ ´ëÇÑ °ü½É Áõ°¡, ÀÓ»ó½ÃÇè ¼ö Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù.
ÀÇ·á ±â°ü ¹× ÀÓ»ó ¿¬±¸ ºÐ¾ß¿¡¼ AI ±â¹Ý ÀÓ»ó µ¥ÀÌÅÍ ºÐ¼® ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÏ°í ÀÖ´Â °ÍÀº ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä µ¿ÀÎÀ̸ç, AI ÀÚµ¿È´Â ¼³¹® Á¶»ç, °Ë»ç °á°ú, ȯÀÚ ±â·Ï µî ´Ù¾çÇÑ ¼Ò½º·ÎºÎÅÍ µ¥ÀÌÅ͸¦ ¼öÁýÇÏ°í ºÐ¼®ÇÏ´Â µ¥ ÇʼöÀûÀ̸ç, AI ¾Ë°í¸®ÁòÀº ½Å¼ÓÇÑ µ¥ÀÌÅÍ ºÐ¼®À» ÅëÇØ ¿©·¯ ±â°ü¿¡¼ ÀÓ»ó ¿î¿µÀÇ È¿À²¼ºÀ» ³ôÀÏ ¼ö ÀÖ´Â ±ÍÁßÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ºÐ¼®ÇÒ ¼ö ÀÖÀ¸¸ç, ¿©·¯ ±â°ü¿¡¼ ÀÓ»ó ¿î¿µÀÇ È¿À²¼ºÀ» ³ôÀÏ ¼ö ÀÖ´Â ±ÍÁßÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, ¸Þµðµ¥ÀÌÅÍ´Â 2022³â 10¿ù ºòµ¥ÀÌÅÍ ¸ðµ¨¸µ ±â¼úÀ» È°¿ëÇØ Å°¸Þ¶ó Ç׿ø ¼ö¿ëü T ¼¼Æ÷ Ä¡·á¸¦ ¹Þ´Â ȯÀÚ¿¡¼ ÁßÁõ »çÀÌÅäÄ«ÀÎ ¹æÃâ ÁõÈıº ¹ßº´À» ¿¹ÃøÇÏ´Â °Ë»ç ¸¶Ä¿¸¦ ã¾Æ³Â½À´Ï´Ù.
Äڷγª19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ ÇコÄÉ¾î ºÐ¾ß´Â Å©°Ô ¼ºÀåÇßÀ¸¸ç, ±ÞÁõÇϴ ȯÀÚ µ¥ÀÌÅ͸¦ °ü¸®ÇÒ ¼ö ÀÖ´Â µðÁöÅÐ ¼Ö·ç¼Ç°ú °í±Þ ºÐ¼® µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çß½À´Ï´Ù. ºÐ¼® Ç÷§ÆûÀ» ÅëÇØ ÆÒµ¥¹Í ±â°£ µ¿¾È »ý¼ºµÈ ¹æ´ëÇÑ ÀÓ»ó µ¥ÀÌÅ͸¦ È¿°úÀûÀ¸·Î ó¸®ÇÒ ¼ö ÀÖ°Ô µÇ¾ú°í, À̸¦ ÅëÇØ ¿¬±¸ ¹× ÀÇ·á Àü¹®°¡µéÀÌ ´õ ³ªÀº °á°ú¸¦ ¾ò°í, Ãß¼¼¸¦ ¿¹ÃøÇÏ°í, Áúº´ ÀüÆÄ ÆÐÅÏ¿¡ ´ëÇÑ ´õ ±íÀº ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.
½ÃÀå ³» ÁÖ¿ä ±â¾÷µéÀº ½ÃÀå ÁöÀ§¸¦ °ÈÇϱâ À§ÇØ ÆÄÆ®³Ê½Ê, Á¦ÈÞ, ½ÅÁ¦Ç° Ãâ½Ã, Àμö, »ç¾÷ È®Àå µî ´Ù¾çÇÑ Àü·«Àû ³ë·ÂÀ» ±â¿ïÀÌ°í ÀÖÀ¸¸ç, 2023³â 3¿ù ½Ã³×¿À½º Çコ(Syneos Health)¿Í KX´Â ÀÓ»ó½ÃÇèÀÇ È¿À²¼º, ½ÃÀå Ãâ½Ã ±â°£ ´ÜÃà, È¿°úÀûÀΠȯÀÚ Ä¡·á¸¦ À§ÇÑ ºñ¿ë Àý°¨À» ¸ñÇ¥·Î Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ü°áÇÑ ¹Ù ÀÖ½À´Ï´Ù. ºñ¿ë Àý°¨À» À§ÇÑ Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ü°áÇÏ¿´½À´Ï´Ù. ÀÌ Àü·«Àû ÆÄÆ®³Ê½ÊÀº ¾÷°è ÃÖÃÊ·Î µ¥ÀÌÅÍ Å¸ÀÓÇϿ콺(Data Timehouse)¸¦ ÅëÇØ AI, ML, µ¥ÀÌÅÍ ±â¹Ý ¿¹Ãø ºÐ¼® ±â´ÉÀ» Á¦°øÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Çõ½ÅÀûÀÎ µ¥ÀÌÅÍ ¹× AI °ü¸® ¿£ÁøÀº µðÁöÅÐ ÀüȯÀ¸·Î ÀÎÇØ »ý¼ºµÇ´Â ½Ã°£Àû µ¥ÀÌÅ͸¦ ó¸®Çϵµ·Ï ¼³°èµÇ¾î °í°´ÀÌ º¹ÀâÇÑ ÀÇ·á °ü·Ã ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù.
ÀÓ»ó µ¥ÀÌÅÍ ºÐ¼® ¼Ö·ç¼Ç ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- ¹èÄ¡ ºÎ¹®º°·Î º¸¸é, Ŭ¶ó¿ìµå ±â¹Ý ºÎ¹®ÀÌ 2023³â 55.58%ÀÇ ÃÖ´ë ½ÃÀå Á¡À¯À²·Î ¿ìÀ§¸¦ Á¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, »ç¿ëÀÚ Ä£ÈÀûÀÎ ±â¼ú°ú ºñ¿ë È¿À²¼ºÀÇ Ã¤Åà Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÏ´Â ºÎ¹®ÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ÀÀ¿ë ºÐ¾ßº°·Î º¸¸é, ÀÓ»ó½ÃÇè ºÐ¾ß°¡ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Âµ¥, ÀÌ´Â ÀÓ»ó µ¥ÀÌÅÍ ºÐ¼® ¼Ö·ç¼Ç µµÀÔ¿¡ µû¸¥ ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁ³±â ¶§¹®À¸·Î ºÐ¼®µË´Ï´Ù.
- 2023³â ºÏ¹Ì°¡ ÀÓ»ó µ¥ÀÌÅÍ ºÐ¼® ¼Ö·ç¼Ç »ê¾÷À» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ÀÌ Áö¿ªÀÇ ¼±ÁøÀûÀÎ ÇコÄɾî ÀÎÇÁ¶ó¿Í Á¤Ã¥ ¹× À̴ϼÅƼºê¸¦ ÅëÇÑ Á¤ºÎÀÇ Áö¿ø ´öºÐÀÔ´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå ÁÖ¿ä ¿ä¾à
Á¦3Àå ÀÓ»ó µ¥ÀÌÅÍ ºÐ¼® ¼Ö·ç¼Ç ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- »óÀ§ ½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- ¾÷°è ¹ë·ùüÀÎ ºÐ¼®
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ¾÷°è °úÁ¦
- ÀÓ»ó µ¥ÀÌÅÍ ºÐ¼® ¼Ö·ç¼Ç ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - PorterÀÇ Five Forces ºÐ¼®
- PESTEL ºÐ¼®
- ÁÖ¿ä °Å·¡¿Í Àü·«Àû Á¦ÈÞ ºÐ¼®
- ½ÃÀå ÁøÃâ Àü·«
Á¦4Àå ÀÓ»ó µ¥ÀÌÅÍ ºÐ¼® ¼Ö·ç¼Ç ½ÃÀå : Àü°³ ÃßÁ¤¡¤µ¿Ç⠺м®
- Á¤ÀÇ¿Í ¹üÀ§
- ºÎ¹® ´ë½Ãº¸µå
- Àü°³ Çüź° ¼¼°èÀÇ ÀÓ»ó µ¥ÀÌÅÍ ºÐ¼® ¼Ö·ç¼Ç ½ÃÀå Àü¸Á
Á¦5Àå ÀÓ»ó µ¥ÀÌÅÍ ºÐ¼® ¼Ö·ç¼Ç ½ÃÀå : ¿ëµµ ÃßÁ¤¡¤µ¿Ç⠺м®
- Á¤ÀÇ¿Í ¹üÀ§
- ºÎ¹® ´ë½Ãº¸µå
- ¿ëµµº° ¼¼°èÀÇ ÀÓ»ó µ¥ÀÌÅÍ ºÐ¼® ¼Ö·ç¼Ç ½ÃÀå Àü¸Á
Á¦6Àå ÀÓ»ó µ¥ÀÌÅÍ ºÐ¼® ¼Ö·ç¼Ç ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®
- Áö¿ª ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
- Áö¿ª ½ÃÀå ´ë½Ãº¸µå
- Áö¿ª ½ÃÀå ½º³À¼ô
- ½ÃÀå ±Ô¸ð, ¿¹Ãø, ¾ç ¹× µ¿Ç⠺м®, 2018-2030³â
- ºÏ¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ÀÌÅ»¸®¾Æ
- ½ºÆäÀÎ
- ½º¿þµ§
- µ§¸¶Å©
- ³ë¸£¿þÀÌ
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- Çѱ¹
- ű¹
- È£ÁÖ
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«°øȱ¹
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- Äí¿þÀÌÆ®
Á¦7Àå °æÀï ±¸µµ
- ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÇ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
- ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)
- ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
- ÁÖ¿ä ±â¾÷ ½ÃÀå ÇöȲ ºÐ¼®, 2023³â
- ±â¾÷ °³¿ä
- Optum, Inc.
- SAS Institute Inc.
- IQVIA
- Health Catalyst
- eClinical Solutions LLC
- JMP Statistical Discovery LLC.
- OSP
- BD
- Dassault Systems
- Cognizant
LSH 24.03.25
Clinical Data Analytics Solutions Market Growth & Trends:
The global clinical data analytics solutions market size is anticipated to reach USD 7.5 billion by 2030, expanding at a notable CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. Major factors driving the market growth include the increasing need for advanced technologies in healthcare organizations, increasing focus on population health management, and a growing number of clinical trials.
Increasing adoption of AI-powered clinical data analytics solutions in healthcare facilities and clinical research is a key driver of market growth. AI automation is vital in gathering and analyzing data from various sources, such as surveys, lab results, and patient records. AI algorithms enable rapid data analysis, delivering valuable insights that enhance the efficiency of clinical operations at multiple sites. For instance, in October 2022, Medidata utilized a big data modeling technique to identify lab markers that predict the development of severe cytokine release syndrome in patients undergoing chimeric antigen receptor T-cell therapy.
The COVID-19 pandemic led to significant growth in the healthcare sector, fueled by rising demand for digital solutions and advanced analytics tools to manage the surge in patient data. Effectively handling the extensive clinical data generated during the pandemic was made possible through analytics platforms, enabling researchers and healthcare professionals to obtain better outcomes, predict trends, and gain deeper insights into disease transmission patterns.
Key players in the market are engaged in strategic initiatives such as partnerships, collaborations, new product launches, acquisitions, and expansions to strengthen their market position. In March 2023, Syneos Health and KX formed a strategic partnershipwith the goal of enhancing clinical trial efficiency, reducing time to market, and lowering costs for effective patient therapies. This strategic partnership focuses on providing AI, ML, and data-driven predictive analytics capabilities through the industry's first Data Timehouse. Furthermore, this innovative data and AI management engine is designed to handle temporal data generated by digital transformation, helping customers make complex healthcare decisions.
Clinical Data Analytics Solutions Market Report Highlights:
- Based on deployment, the cloud-based segment dominated with the largest market share of 55.58% in 2023 and is anticipated to be the fastest-growing segment over the forecast period owing to the increasing adoption of user-friendly technology and cost-effectiveness
- Based on application, the clinical trials segment held the largest market share in 2023, owing to the increasing awareness of the benefits associated with the adoption of clinical data analytics solutions
- In 2023, North America dominated the clinical data analytics solutions industry. This was attributed to the region's advanced healthcare infrastructure and government support through policies and initiatives
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Deployment
- 1.1.2. Application
- 1.1.3. Regional scope
- 1.1.4. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.1.1. Approach 1: Commodity flow approach
- 1.6.2. Volume price analysis (Model 2)
- 1.6.2.1. Approach 2: Volume price analysis
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
- 1.9.1. Objective 1
- 1.9.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Deployment outlook
- 2.2.2. Application outlook
- 2.2.3. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Clinical Data Analytics Solutions Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Industry Value Chain Analysis
- 3.2.1. Reimbursement framework
- 3.3. Market Dynamics
- 3.3.1. Market Driver Analysis
- 3.3.1.1. Increasing need for advanced technologies in healthcare organizations
- 3.3.1.2. Growing number of clinical trials
- 3.3.1.3. Increasing focus on population health management
- 3.3.1.4. Rising prevalence of chronic diseases
- 3.3.2. Market Restraint Analysis
- 3.3.2.1. Data privacy and theft issues
- 3.3.2.2. Lack of skilled professionals
- 3.3.3. Industry Challenge
- 3.4. Clinical Data Analytics Solutions Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.3. Major Deals & Strategic Alliances Analysis
- 3.4.4. Market Entry Strategies
Chapter 4. Clinical Data Analytics Solutions Market: Deployment Estimates & Trend Analysis
- 4.1. Definitions and Scope
- 4.1.1. Cloud-based
- 4.1.2. On-premise
- 4.2. Segment Dashboard
- 4.3. Global Clinical Data Analytics Solutions Market by Deployment Outlook
- 4.3.1. Cloud-based
- 4.3.1.1. Cloud-based market estimates and forecast 2018 to 2030 (USD Million)
- 4.3.2. On-premise
- 4.3.2.1. On-premise market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. Clinical Data Analytics Solutions Market: Application Estimates & Trend Analysis
- 5.1. Definitions and Scope
- 5.1.1. Clinical Decision Support
- 5.1.2. Clinical Trials
- 5.1.3. Regulatory Compliance
- 5.1.4. Others
- 5.2. Segment Dashboard
- 5.3. Global Clinical Data Analytics Solutions Market by Application Outlook
- 5.3.1. Clinical Decision Support
- 5.3.1.1. Cinical decision support market estimates and forecast 2018 to 2030 (USD Million)
- 5.3.2. Clinical Trials
- 5.3.2.1. Clinical trials market estimates and forecast 2018 to 2030 (USD Million)
- 5.3.3. Regulatory Compliance
- 5.3.3.1. Regulatory compliance market estimates and forecast 2018 to 2030 (USD Million)
- 5.3.4. Others
- 5.3.4.1. Others market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. Clinical Data Analytics Solutions Market: Regional Estimates & Trend Analysis
- 6.1. Regional Market Share Analysis, 2023 & 2030
- 6.2. Regional Market Dashboard
- 6.3. Regional Market Snapshot
- 6.4. Market Size, & Forecasts, Volume and Trend Analysis, 2018 to 2030:
- 6.5. North America
- 6.5.1. Market estimates and forecast, 2018 - 2030
- 6.5.2. U.S.
- 6.5.2.1. Market estimates and forecast, 2018 - 2030
- 6.5.3. Canada
- 6.5.3.1. Market estimates and forecast, 2018 - 2030
- 6.6. Europe
- 6.6.1. UK
- 6.6.1.1. Market estimates and forecast, 2018 - 2030
- 6.6.2. Germany
- 6.6.2.1. Market estimates and forecast, 2018 - 2030
- 6.6.3. France
- 6.6.3.1. Market estimates and forecast, 2018 - 2030
- 6.6.4. Italy
- 6.6.4.1. Market estimates and forecast, 2018 - 2030
- 6.6.5. Spain
- 6.6.5.1. Market estimates and forecast, 2018 - 2030
- 6.6.6. Sweden
- 6.6.6.1. Market estimates and forecast, 2018 - 2030
- 6.6.7. Denmark
- 6.6.7.1. Market estimates and forecast, 2018 - 2030
- 6.6.8. Norway
- 6.6.8.1. Market estimates and forecast, 2018 - 2030
- 6.7. Asia Pacific
- 6.7.1. Japan
- 6.7.1.1. Market estimates and forecast, 2018 - 2030
- 6.7.2. China
- 6.7.2.1. Market estimates and forecast, 2018 - 2030
- 6.7.3. India
- 6.7.3.1. Market estimates and forecast, 2018 - 2030
- 6.7.4. South Korea
- 6.7.4.1. Market estimates and forecast, 2018 - 2030
- 6.7.5. Thailand
- 6.7.5.1. Market estimates and forecast, 2018 - 2030
- 6.7.6. Australia
- 6.7.6.1. Market estimates and forecast, 2018 - 2030
- 6.8. Latin America
- 6.8.1. Brazil
- 6.8.1.1. Market estimates and forecast, 2018 - 2030
- 6.8.2. Mexico
- 6.8.2.1. Market estimates and forecast, 2018 - 2030
- 6.8.3. Argentina
- 6.8.3.1. Market estimates and forecast, 2018 - 2030
- 6.9. MEA
- 6.9.1. South Africa
- 6.9.1.1. Market estimates and forecast, 2018 - 2030
- 6.9.2. Saudi Arabia
- 6.9.2.1. Market estimates and forecast, 2018 - 2030
- 6.9.3. UAE
- 6.9.3.1. Market estimates and forecast, 2018 - 2030
- 6.9.4. Kuwait
- 6.9.4.1. Market estimates and forecast, 2018 - 2030
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis, By Key Market Participants
- 7.2. Company/Competition Categorization
- 7.3. Key Company Market Share Analysis, 2023
- 7.4. Key Company Market Position Analysis, 2023
- 7.5. Company Profiles
- 7.5.1. Optum, Inc.
- 7.5.1.1. Company overview
- 7.5.1.2. Financial performance
- 7.5.1.3. Product benchmarking
- 7.5.1.4. Strategic initiatives
- 7.5.2. SAS Institute Inc.
- 7.5.2.1. Company overview
- 7.5.2.2. Financial performance
- 7.5.2.3. Product benchmarking
- 7.5.2.4. Strategic initiatives
- 7.5.3. IQVIA
- 7.5.3.1. Company overview
- 7.5.3.2. Financial performance
- 7.5.3.3. Product benchmarking
- 7.5.3.4. Strategic initiatives
- 7.5.4. Health Catalyst
- 7.5.4.1. Company overview
- 7.5.4.2. Financial performance
- 7.5.4.3. Product benchmarking
- 7.5.4.4. Strategic initiatives
- 7.5.5. eClinical Solutions LLC
- 7.5.5.1. Company overview
- 7.5.5.2. Financial performance
- 7.5.5.3. Product benchmarking
- 7.5.5.4. Strategic initiatives
- 7.5.6. JMP Statistical Discovery LLC.
- 7.5.6.1. Company overview
- 7.5.6.2. Financial performance
- 7.5.6.3. Product benchmarking
- 7.5.6.4. Strategic initiatives
- 7.5.7. OSP
- 7.5.7.1. Company overview
- 7.5.7.2. Financial performance
- 7.5.7.3. Product benchmarking
- 7.5.7.4. Strategic initiatives
- 7.5.8. BD
- 7.5.8.1. Company overview
- 7.5.8.2. Financial performance
- 7.5.8.3. Product benchmarking
- 7.5.8.4. Strategic initiatives
- 7.5.9. Dassault Systems
- 7.5.9.1. Company overview
- 7.5.9.2. Financial performance
- 7.5.9.3. Product benchmarking
- 7.5.9.4. Strategic initiatives
- 7.5.10. Cognizant
- 7.5.10.1. Company overview
- 7.5.10.2. Financial performance
- 7.5.10.3. Product benchmarking
- 7.5.10.4. Strategic initiatives